Evaluation of a personalized, dose-sparing revaccination strategy in hepatitis B vaccine non-responders

Christian Beulens, Stijn F H Raven, Cornelia H M van Jaarsveld, Inge van Loo, Greet Boland, Leo G Visser, Christian J P A Hoebe, Ann C T M Vossen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVES: The detection of low levels of antibodies against HBsAg (anti-HBs) below 10 IU/L in non-responders after a primary hepatitis B vaccination, is associated with seroconversion after revaccination. We compared the diagnostic performance of four anti-HBs assays in non-responders in their ability to differentiate between absence or presence of low levels of anti-HBs and propose a revaccination strategy guided by anti-HBs titres.

METHODS: Non-responders were revaccinated with Fendrix 20 μg at 0, 1 and 2 months. Anti-HBs titres were determined by Abbott Architect, Diasorin Liaison, Roche Cobas and Siemens ADVIA Centaur. Inter-assay agreement was evaluated with Cohen's Kappa (k) in baseline samples between zero-responders without detectable antibodies and poor-responders with detectable antibodies < 10 IU/L. Seroconversion rates and geometric mean titres were analysed at 0, 1 and 3 months. A titre-based strategy (one revaccination dose and anti-HBs measurement followed by two more revaccination doses if required) was compared with the standard revaccination series of 3 doses.

RESULTS: 57 participants were included in the analysis. k was ≥ 0.65 for all assays except ADVIA (k ≤ 0.41). After one revaccination dose all assays detected a mean seroconversion rate in zero-responders of 42.9%, compared to 85.1% in poor-responders. The difference between zero- and poor-responders in seroconversion rate per assay was significant (p < 0.05). After three revaccination doses the mean seroconversion rate was 88.2% in zero-responders and 98.5% in poor-responders (p > 0.286 per assay). A titre-based strategy reduced the amount of revaccinations by 17% compared with the standard.

CONCLUSIONS: All assays demonstrated a comparable difference in seroconversion rate between zero- and poor-responders after one revaccination dose. The revaccination strategy could be optimised by differentiation between zero- and poor-responders followed by a titre-guided schedule.

Original languageEnglish
Pages (from-to)3210-3215
Number of pages6
JournalVaccine
Volume40
Issue number23
DOIs
Publication statusPublished - 20 May 2022

Keywords

  • Hepatitis B antibodies
  • Hepatitis B vaccines
  • Hepatitis B virus
  • Hepatitis/prevention and control
  • Anti-HBs
  • ANTIBODY-RESPONSE
  • IMMUNOGENICITY
  • PERFORMANCE
  • ADULTS
  • ASSAYS

Cite this